Fluidigm Corp. (NASDAQ:FLDM) fell 2.2% during mid-day trading on Thursday . The stock traded as low as $8.88 and last traded at $8.91, with a volume of 67,940 shares changing hands. The stock had previously closed at $9.11.

Several brokerages have issued reports on FLDM. Mizuho cut their price target on Fluidigm Corp. from $11.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, May 5th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $13.00 price target on shares of Fluidigm Corp. in a report on Friday, May 6th. Zacks Investment Research downgraded Fluidigm Corp. from a “buy” rating to a “hold” rating in a report on Monday, July 11th. Finally, Deutsche Bank AG began coverage on Fluidigm Corp. in a report on Wednesday, June 1st. They set a “buy” rating for the company. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Fluidigm Corp. presently has an average rating of “Buy” and an average target price of $13.67.

The company’s market cap is $255.23 million. The company has a 50-day moving average price of $9.60 and a 200 day moving average price of $8.93.

Fluidigm Corp. (NASDAQ:FLDM) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.64) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by $0.06. The firm earned $28.20 million during the quarter, compared to analysts’ expectations of $29.62 million. The firm’s quarterly revenue was down 1.5% on a year-over-year basis. During the same period last year, the company posted ($0.53) EPS. On average, equities analysts expect that Fluidigm Corp. will post ($2.31) EPS for the current fiscal year.

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.